1. Home
  2. CAMT vs BLCO Comparison

CAMT vs BLCO Comparison

Compare CAMT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camtek Ltd.

CAMT

Camtek Ltd.

HOLD

Current Price

$157.26

Market Cap

6.9B

Sector

Technology

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$17.74

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAMT
BLCO
Founded
1987
1853
Country
Employees
N/A
N/A
Industry
Electronic Components
Ophthalmic Goods
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CAMT
BLCO
Price
$157.26
$17.74
Analyst Decision
Buy
Hold
Analyst Count
11
13
Target Price
$128.45
$17.25
AVG Volume (30 Days)
561.3K
364.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.66
$8.08
Revenue Next Year
$6.12
$5.85
P/E Ratio
$155.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$47.41
$10.45
52 Week High
$164.21
$17.91

Technical Indicators

Market Signals
Indicator
CAMT
BLCO
Relative Strength Index (RSI) 60.35 62.61
Support Level $154.26 $16.60
Resistance Level $163.19 $17.45
Average True Range (ATR) 8.70 0.51
MACD 0.37 0.07
Stochastic Oscillator 76.41 92.22

Price Performance

Historical Comparison
CAMT
BLCO

About CAMT Camtek Ltd.

Camtek Ltd is engaged in the manufacturing of metrology and inspection equipment and software solutions for the semiconductor industry. Its systems inspect wafers for various semiconductor market segments, including Advanced Packaging, Heterogenous Integration (HI), Compound Semiconductors, Memory, and foundries among others. Geographically, it derives maximum revenue from China followed by Asia Pacific, Korea, United States, and Europe. The company's products and services include Surface Inspection, Bump Inspection and Metrology, and others.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: